AbCellera, Incyte to Accelerate Discovery, Development of Therapeutic Antibodies in Oncology

AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology.

"We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need," said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. "We look forward to working as an extension of Incyte’s team to address complex antibody discovery challenges and accelerate the development of Incyte’s preclinical pipeline of oncology medicines."

"This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer," said Patrick Mayes, Ph.D., Vice President, BioTherapeutics at Incyte. "We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology."

Under the financial terms of the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.

https://finance.yahoo.com/news/abcellera-announces-collaboration-incyte-accelerate-130000248.html

Sana Bio filing

 At the Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023, a company spokesperson of Sana Biotechnology, Inc. (the “Company”) announced that the Company expects to file an investigational new drug application for its SC291 product candidate in autoimmune diseases in the fourth quarter of 2023 and expects clinical data from the evaluation of SC291 in autoimmune diseases in 2024.

 

On September 13, 2023, the Company released an updated corporate presentation (the “Corporate Presentation”), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information furnished with this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

https://last10k.com/sec-filings/SANA/0000950170-23-047822.htm

Hoth: Positive Results v. Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

 Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT.

HT-KIT Shows Positive Results in AML

Positive Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University

https://finance.yahoo.com/news/hoth-therapeutics-announces-positive-results-121600954.html

Mainz Biomarker Study: Sensitivity for Colorectal Cancer of 94%

 Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study. The ColoFuture study is a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe and in select international territories. The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.

“The data generated from the ColoFuture study exceeded our expectations. As we look forward to publishing and presenting the full dataset at a forthcoming medical conference, we eagerly await the outcome from our eAArly DETECT clinical trial which remains on track to report results in Q4 of this year,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.

The portfolio of mRNA biomarkers evaluated in the ColoFuture study was acquired from the Université de Sherbrooke (January 2022) to potentially enhance ColoAlert®’s technical profile to further extend its capability to include the identification of advanced adenomas (AA), a type of pre-cancerous polyp often attributed to CRC, and to increase the diagnostic sensitivity and specificity rates for CRC. In Sherbrooke’s pioneering work, researchers tested a battery of novel transcriptional mRNA biomarkers using samples obtained from patients diagnosed with CRC or as having an advanced adenoma and identified a subset of mRNA biomarkers that provided the greatest sensitivity and specificity of detection (Herring et al. 2021). Mainz Biomed specifically selected those mRNA biomarkers which demonstrated not just the ability to detect a disease signal from samples of patients who were known to have colorectal cancer, but also the unique potential to identify a signal from samples of patients with advanced adenomas. The power to detect lesions in a pre-cancerous stage can change the entire CRC diagnostic landscape. If advanced adenomas are identified early, they are curable. By treating the patient before the polyps can progress to a cancerous stage, CRC can be prevented.

https://finance.yahoo.com/news/mainz-biomed-colofuture-study-evaluating-070100125.html

Novo Nordisk conducts a two-for-one stock split

As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, Novo Nordisk's Board of Directors has approved a split of the trading units of the Novo Nordisk B shares listed on Nasdaq Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE) in a two-for-one ratio.

Novo Nordisk’s B shares have been listed on Nasdaq Copenhagen in trading units of DKK 0.20 and its American Depositary Receipts (ADRs) that equal B-shares of DKK 0.20 have been listed on New York Stock Exchange (NYSE).

Consequently, the trading unit of the Novo Nordisk B shares listed on Nasdaq Copenhagen has been changed from DKK 0.20 to DKK 0.10 as of 13 September 2023. The ADRs will similarly be split as of 20 September 2023 to maintain the one-to-one relationship between the B-share and the ADR.

https://finance.yahoo.com/news/novo-nordisk-conducts-two-one-053000448.html

Ocugen: Positive Update in Phase 1/2 Trial of Gene Therapy Product Candidate for Retinitis Pigmentosa

 

• Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to date

• Clinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance Visual Acuity (LLVA) among treated eyes

• 83% (10/12) of subjects demonstrated stabilization or improvement in treated eye either on BCVA or LLVA or MLMT scores from baseline

• Notably, 86% (6/7) of RHO mutation subjects experienced either stabilization of or increase in MLMT scores from baseline including a subset of 29% (2/7) that demonstrated a 3 Lux luminance level improvement

https://finance.yahoo.com/news/ocugen-announces-positive-clinical-study-121500823.html

NOVO NORDISK : Deutsche Bank gives a Buy rating

 Analyst Emmanuel Papadakis from Deutsche Bank research considers the stock attractive and recommends it with a Buy rating. The target price is still set at DKK 1550.

https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-Deutsche-Bank-gives-a-Buy-rating-44834331/